Panel wants FDA to approve Xarelto as preventive stroke therapy

An FDA advisory panel endorsed the approval of anticoagulant Xarelto to prevent stroke in patients with atrial fibrillation. Earlier, agency staff questioned whether Xarelto is superior to standard drug warfarin. Xarelto developers Johnson & Johnson and Bayer expect an FDA decision in November.

View Full Article in:

New York Times (tiered subscription model), The · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Director of Accreditation
Meridian Health Plan
Detroit, MI
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ